![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 296, Issue 2, 235-242, February 2001
Department of Medicine and Therapeutics, University of Aberdeen
Medical School, Foresterhill, Aberdeen, United Kingdom (J.E.D., K.T.,
F.P.C., S.P.L., M.J.R.); Department of Chemistry, University of Utah,
Salt Lake City, Utah (C.D.P.); Maui Agricultural Research Center,
University of Hawaii, Kula, Hawaii (F.M.H.); and Procter & Gamble
Pharmaceuticals, Health Care Research Center, Mason, Ohio (F.H.E.)
It has long been known that small changes to the structure of the
R2 side chain of nitrogen-containing bisphosphonates can
dramatically affect their potency for inhibiting bone resorption in
vitro and in vivo, although the reason for these differences in
antiresorptive potency have not been explained at the level of a
pharmacological target. Recently, several nitrogen-containing
bisphosphonates were found to inhibit osteoclast-mediated bone
resorption in vitro by inhibiting farnesyl diphosphate synthase,
thereby preventing protein prenylation in osteoclasts. In this study,
we examined the potency of a wider range of nitrogen-containing
bisphosphonates, including the highly potent, heterocycle-containing
zoledronic acid and minodronate (YM-529). We found a clear correlation
between the ability to inhibit farnesyl diphosphate synthase in vitro, to inhibit protein prenylation in cell-free extracts and in purified osteoclasts in vitro, and to inhibit bone resorption in vivo. The
activity of recombinant human farnesyl diphosphate synthase was
inhibited at concentrations 
1 nM zoledronic acid or minodronate, the
order of potency (zoledronic acid 
minodronate > risedronate > ibandronate > incadronate > alendronate > pamidronate) closely matching the order of
antiresorptive potency. Furthermore, minor changes to the structure of
the R2 side chain of heterocycle-containing
bisphosphonates, giving rise to less potent inhibitors of bone
resorption in vivo, also caused a reduction in potency up to
~300-fold for inhibition of farnesyl diphosphate synthase in vitro.
These data indicate that farnesyl diphosphate synthase is the major
pharmacological target of these drugs in vivo, and that small changes
to the structure of the R2 side chain alter antiresorptive
potency by affecting the ability to inhibit farnesyl diphosphate synthase.
This article has been cited by other articles:
|
|
 |
|
  F. P. Coxon An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity IBMS BoneKEy, October 1, 2008; 5(10): 357 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Miller, P. D. Delmas, R. Lindsay, N. B. Watts, M. Luckey, J. Adachi, K. Saag, S. L. Greenspan, E. Seeman, S. Boonen, et al. Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3785 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ottewell, H. Monkkonen, M. Jones, D. V. Lefley, R. E. Coleman, and I. Holen Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer J Natl Cancer Inst, August 20, 2008; 100(16): 1167 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ottewell, B. Deux, H. Monkkonen, S. Cross, R. E. Coleman, P. Clezardin, and I. Holen Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo Clin. Cancer Res., July 15, 2008; 14(14): 4658 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Simonen, Y. Ibig-Rehm, G. Hofmann, J. Zimmermann, G. Albrecht, M. Magnier, V. Heidinger, and D. Gabriel High-Content Assay to Study Protein Prenylation J Biomol Screen, July 1, 2008; 13(6): 456 - 467. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Dudakovic, A. J. Wiemer, K. M. Lamb, L. A. Vonnahme, S. E. Dietz, and R. J. Hohl Inhibition of Geranylgeranyl Diphosphate Synthase Induces Apoptosis through Multiple Mechanisms and Displays Synergy with Inhibition of Other Isoprenoid Biosynthetic Enzymes J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1028 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Holderness, L. Jackiw, E. Kimmel, H. Kerns, M. Radke, J. F. Hedges, C. Petrie, P. McCurley, P. M. Glee, A. Palecanda, et al. Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells J. Immunol., November 15, 2007; 179(10): 6468 - 6478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates J. Dent. Res., November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ling, Z.-H. Li, K. Miranda, E. Oldfield, and S. N. J. Moreno The Farnesyl-diphosphate/Geranylgeranyl-diphosphate Synthase of Toxoplasma gondii Is a Bifunctional Enzyme and a Molecular Target of Bisphosphonates J. Biol. Chem., October 19, 2007; 282(42): 30804 - 30816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. McDonald, A. Schindeler, and D. G. Little Bisphosphonate Treatment and Fracture Repair IBMS BoneKEy, September 1, 2007; 4(9): 236 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fiore, B. Castella, B. Nuschak, R. Bertieri, S. Mariani, B. Bruno, F. Pantaleoni, M. Foglietta, M. Boccadoro, and M. Massaia Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid Blood, August 1, 2007; 110(3): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. G. Russell Bisphosphonates: Mode of Action and Pharmacology Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., October 15, 2006; 12(20): 6222s - 6230s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Thompson and M. J. Rogers Bisphosphonates and {gamma}{delta} T-Cells: New Insights into Old Drugs IBMS BoneKEy, August 1, 2006; 3(8): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Nase and J. B. Suzuki Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc, August 1, 2006; 137(8): 1115 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ortiz-Gomez, C. Jimenez, A. M. Estevez, J. Carrero-Lerida, L. M. Ruiz-Perez, and D. Gonzalez-Pacanowska Farnesyl Diphosphate Synthase Is a Cytosolic Enzyme in Leishmania major Promastigotes and Its Overexpression Confers Resistance to Risedronate. Eukaryot. Cell, July 1, 2006; 5(7): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Kavanagh, K. Guo, J. E. Dunford, X. Wu, S. Knapp, F. H. Ebetino, M. J. Rogers, R. G. G. Russell, and U. Oppermann The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs PNAS, May 16, 2006; 103(20): 7829 - 7834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thompson, M. J. Rogers, F. P. Coxon, and J. C. Crockett Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis Mol. Pharmacol., May 1, 2006; 69(5): 1624 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Thompson, J. Rojas-Navea, and M. J. Rogers Alkylamines cause V{gamma}9V{delta}2 T-cell activation and proliferation by inhibiting the mevalonate pathway Blood, January 15, 2006; 107(2): 651 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, T. Karashima, S. Fukata, A. Nomura, C. Kawada, A. Kurabayashi, M. Furihata, Y. Ohtsuki, and T. Shuin Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma Clin. Cancer Res., September 15, 2005; 11(18): 6669 - 6677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid, P. Miller, K. Lyles, W. Fraser, J. P. Brown, Y. Saidi, P. Mesenbrink, G. Su, J. Pak, K. Zelenakas, et al. Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease N. Engl. J. Med., September 1, 2005; 353(9): 898 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A Licata Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates Ann. Pharmacother., April 1, 2005; 39(4): 668 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barrett, E. Worth, F. Bauss, and S. Epstein Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update J. Clin. Pharmacol., September 1, 2004; 44(9): 951 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Green Bisphosphonates: Preclinical Review Oncologist, September 1, 2004; 9(suppl_4): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Langston and S. H. Ralston Management of Paget's disease of bone Rheumatology, August 1, 2004; 43(8): 955 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berenson and R. Hirschberg Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, June 1, 2004; 9(3): 319 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Ruegg Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death: EVIDENCE FOR THE SUPPRESSION OF SUSTAINED ACTIVATION OF FOCAL ADHESION KINASE AND PROTEIN KINASE B/Akt J. Biol. Chem., October 31, 2003; 278(44): 43603 - 43614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H L Neville-Webbe and R E Coleman The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliative Medicine, September 1, 2003; 17(6): 539 - 553. [Abstract] [PDF]
|
|
|
|
|
|
A. Montalvetti, A. Fernandez, J. M. Sanders, S. Ghosh, E. Van Brussel, E. Oldfield, and R. Docampo Farnesyl Pyrophosphate Synthase Is an Essential Enzyme in Trypanosoma brucei. IN VITRO RNA INTERFERENCE AND IN VIVO INHIBITION STUDIES J. Biol. Chem., May 2, 2003; 278(19): 17075 - 17083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, and G. De Libero Human T Cell Receptor {gamma}{delta} Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells J. Exp. Med., January 20, 2003; 197(2): 163 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Adam, S. Hecht, W. Eisenreich, J. Kaiser, T. Grawert, D. Arigoni, A. Bacher, and F. Rohdich Biosynthesis of terpenes: Studies on 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase PNAS, September 17, 2002; 99(19): 12108 - 12113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Lehenkari, M. Kellinsalmi, J. P. Napankangas, K. V. Ylitalo, J. Monkkonen, M. J. Rogers, A. Azhayev, H. K. Vaananen, and I. E. Hassinen Further Insight into Mechanism of Action of Clodronate: Inhibition of Mitochondrial ADP/ATP Translocase by a Nonhydrolyzable, Adenine-Containing Metabolite Mol. Pharmacol., May 1, 2002; 61(5): 1255 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Coxon, M. H. Helfrich, B. Larijani, M. Muzylak, J. E. Dunford, D. Marshall, A. D. McKinnon, S. A. Nesbitt, M. A. Horton, M. C. Seabra, et al. Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages J. Biol. Chem., December 14, 2001; 276(51): 48213 - 48222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Montalvetti, B. N. Bailey, M. B. Martin, G. W. Severin, E. Oldfield, and R. Docampo Bisphosphonates Are Potent Inhibitors of Trypanosoma cruzi Farnesyl Pyrophosphate Synthase J. Biol. Chem., August 31, 2001; 276(36): 33930 - 33937. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
